Live Analyst Rating Changes 54325 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Sean Laaman
MS

Sean Laaman

Morgan Stanley
Wall Street Analyst
★★★☆☆
#1865
on 13Foresight · ranked by our own returns
57%
Success Rate
+0.9%
Average Return
77 of 134 calls profitable · +14.7% vs benchmark
S&P 500 (SPY)
📈 Across the calls we could measure, roughly 57% of Sean Laaman's ratings turned a profit when each position was held for 1 year — averaging +0.9% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

106 Buy 66 Hold 6 Sell
Sean's Stock Coverage 43 ratings · 2026-11-13
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return vs S&P 500 ⓘ
EXEL
Exelixis
 Oct 30, 2026 HOLD Buy
-34.0% avg upside
34 analysts
$60.00
13.45% Downside
 +0.7% ·
BBIO
BridgeBio Pharma
 Oct 30, 2026 BUY Strong Buy
+26.0% avg upside
36 analysts
$88.00
17.42% Upside
 +4.3% ·
ASND
Ascendis Pharma
 Oct 26, 2026 BUY Strong Buy
+12.2% avg upside
29 analysts
$273.00
8.63% Upside
 +8.9% ·
ARGX
Argenx Se
 Oct 23, 2026 BUY Strong Buy
-8.2% avg upside
48 analysts
$1190.00
33.27% Upside
 +12.3% ·
BBOT
BridgeBio Oncology Therapeutics
 Oct 22, 2026 BUY Strong Buy
+714.3% avg upside
11 analysts
$13.00
396.26% Upside
 -17.5% ·
IMCR
Immunocore Holdings
 Oct 22, 2026 HOLD Strong Buy
+109.0% avg upside
22 analysts
$43.00
40.93% Upside
 -5.1% ·
RVMD
Revolution Medicines
 Oct 22, 2026 BUY Strong Buy
+8.2% avg upside
36 analysts
$255.00
33.26% Upside
 -6.0% ·
BMRN
BioMarin Pharmaceutical
 Oct 21, 2026 BUY Strong Buy
+63.6% avg upside
52 analysts
$122.00
108.52% Upside
 +2.7% ·
JAZZ
Jazz Pharmaceuticals
 Oct 21, 2026 BUY Strong Buy
+16.2% avg upside
36 analysts
$314.00
45.29% Upside
 +14.7% ·
IRON
Disc Medicine
 Oct 20, 2026 BUY Strong Buy
+23.4% avg upside
21 analysts
$92.00
13.73% Upside
 +4.7% ·
ONC
BeOne Medicines
 Oct 16, 2026 BUY Strong Buy
-1.2% avg upside
29 analysts
$425.00
14.76% Upside
 +12.7% ·
RXRX
Recursion Pharmaceuticals
 Oct 16, 2026 HOLD Buy
+92.7% avg upside
12 analysts
$5.90
46.48% Upside
 +2.5% ·
ALEC
Alector
 Oct 14, 2026 SELL Hold
+370.1% avg upside
15 analysts
$3.00
35.83% Upside
 -32.5% ·
CTNM
Contineum Therapeutics, Inc. Class A
 Oct 12, 2026 HOLD Strong Buy
+126.3% avg upside
9 analysts
$17.00
80.94% Upside
 +18.5% ·
ELVN
Enliven Therapeutics
 Oct 05, 2026 BUY Strong Buy
+40.0% avg upside
18 analysts
$70.00
58.20% Upside
 +6.2% ·
AXSM
Axsome Therapeutics
 Sep 25, 2026 HOLD Strong Buy
+63.9% avg upside
30 analysts
$247.00
71.03% Upside
 -25.3% ·
CGEM
Cullinan Management
 Sep 15, 2026 BUY Strong Buy
+135.1% avg upside
16 analysts
$30.00
99.66% Upside
 -47.6% ·
NBIX
Neurocrine
 Sep 11, 2026 HOLD Strong Buy
+27.3% avg upside
37 analysts
$183.00
25.35% Upside
 +8.4% ·
ACAD
ACADIA Pharmaceuticals
 Aug 25, 2026 HOLD Strong Buy
+71.5% avg upside
43 analysts
$28.00
35.91% Upside
 -39.9% ·
MPLT
MapLight Therapeutics, Inc.
 Aug 17, 2026 HOLD Strong Buy
+288.1% avg upside
14 analysts
$21.00
177.01% Upside
 -37.1% ·
ERAS
Erasca
 Aug 17, 2026 HOLD Strong Buy
+46.4% avg upside
14 analysts
$21.00
46.32% Upside
 -13.7% ·
ABSI
AbSci
 Aug 17, 2026 HOLD Strong Buy
+20.1% avg upside
20 analysts
$10.00
10.05% Downside
 -1.1% ·
CGON
CG Oncology, Inc.
 Aug 17, 2026 BUY Strong Buy
+33.1% avg upside
17 analysts
$93.00
43.83% Upside
 -5.8% ·
EIKN
Eikon Therapeutics, Inc.
 Aug 17, 2026 BUY Buy
+344.5% avg upside
6 analysts
$32.00
502.55% Upside
 -44.4% ·
GENB
Generate Biomedicines, Inc.
 Aug 17, 2026 BUY Strong Buy
+85.4% avg upside
6 analysts
$22.00
52.16% Upside
 -19.4% ·
DNLI
Denali Therapeutics
 Aug 07, 2026 BUY Strong Buy
+104.7% avg upside
24 analysts
$40.00
111.15% Upside
 -23.3% ·
HALO
Halozyme
 Aug 07, 2026 BUY Buy
-48.1% avg upside
20 analysts
$105.00
19.74% Downside
 -2.4% ·
SDGR
Schrodinger
 May 14, 2026 HOLD Strong Buy
+7.1% avg upside
16 analysts
$17.00
37.31% Downside
 +41.1% ·
AU:SIG
Sigma Healthcare Ltd
 Aug 28, 2025 BUY Strong Buy
+128.2% avg upside
10 analysts
$3.30
20.92% Upside
 -13.1% ·
CERT
Certara
 Jul 02, 2025 HOLD Buy
+21.4% avg upside
23 analysts
$16.00
45.21% Upside
 -39.3% ·
AU:MPL
Medibank Private
 Feb 12, 2025 HOLD Hold
-13.3% avg upside
2 analysts
$3.95
22.49% Downside
 +17.9% ·
RMD
Resmed
 Aug 01, 2024 HOLD Buy
+4.6% avg upside
27 analysts
 — +31.3% ·
AU:RMD
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh
 Jun 24, 2024 BUY Strong Buy
+15.6% avg upside
11 analysts
$33.70
5.14% Downside
 +41.5% ·
AU:CSL
CSL
 Jun 12, 2024 BUY Strong Buy
+12.2% avg upside
16 analysts
$310.00
54.53% Upside
 -15.8% ·
AU:SHL
Sonic Healthcare Limited
 May 22, 2024 BUY Hold
+23.5% avg upside
12 analysts
$31.65
61.68% Upside
 +7.1% ·
AU:ANN
Ansell
 Apr 09, 2024 HOLD Hold
-22.5% avg upside
9 analysts
$24.14
46.87% Downside
 +16.3% ·
AU:COH
Cochlear
Mar 21, 2024 SELL Buy
+30.8% avg upside
15 analysts
$256.00
78.29% Upside
 +16.9% ·
AU:HLS
Healius Limited
 Feb 28, 2024 SELL Sell
+74.4% avg upside
10 analysts
$1.30
162.68% Upside
 -15.8% ·
AU:NHF
NIB Holdings Ltd
 Feb 27, 2024 HOLD Strong Sell
+1.8% avg upside
2 analysts
$7.35
11.10% Upside
 -5.6% ·
AU:MVF
Monash IVF Group Ltd
 Feb 26, 2024 BUY Buy
+35.5% avg upside
7 analysts
$1.65
129.20% Upside
 -12.5% ·
AU:RHC
Ramsay Health Care
 Nov 28, 2023 HOLD Buy
-14.1% avg upside
14 analysts
$51.60
7.23% Downside
 -17.8% ·
AU:IDX
Integral Diagnostics Ltd.
 Aug 28, 2023 SELL Strong Buy
+63.0% avg upside
12 analysts
$2.75
55.76% Upside
 +7.6% ·
SKHHY
Sonic Healthcare
 Aug 24, 2021 BUY Buy
5 analysts
 — -18.6% ·
🔒 38 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Sean Laaman — Frequently Asked Questions
How accurate are Sean Laaman's stock ratings?
Based on the calls 13Foresight could measure, about 58% of Sean's ratings were profitable over a one-year hold, with an average return of +1.0% per rating, or +14.8% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Sean ranked on 13Foresight?
Sean Laaman is currently ranked #1865 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Sean cover?
Sean most recently has ratings on EXEL, BBIO, ASND, ARGX, BBOT, IMCR, RVMD, BMRN, JAZZ, IRON, ONC, RXRX and 31 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.